|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSA level should be used with caution as an end point in clinical trials using suramin therapy for hormone-refractory prostate cancer.
|
8637045 |
1996 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-PCR for PSA predicts survival duration in a population of men with HRPC.
|
11408497 |
2001 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hormone-refractory prostate cancer (HRPC) encompasses a wide spectrum of patients, including patients with prostate-specific antigen (PSA)--only disease, those with increasing PSA levels yet stable metastatic disease, and those with increasing PSA levels and objective evidence of progressive metastases.
|
14747051 |
2003 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the molecular basis for androgen independent PSA elevation in hormone refractory prostate cancer is unknown.
|
12858361 |
2003 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors conclude that a pVAX/PSA DNA vaccine can induce PSA-specific cellular immune responses in patients with hormone-refractory prostate cancer, thus emphasizing the potential for PSA as a target molecule for the immunotherapy of prostate cancer.
|
16000958 |
2005 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because very limited treatment options are available for recurrent hormone refractory prostate cancer (HRPC), it is imperative to assess whether the prostate-specific antigen (PSA) promoter-based TSTA gene therapy will be functional in HRPC.
|
15897571 |
2005 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
|
16033836 |
2005 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
|
17602304 |
2008 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report here that tissue PSA may be involved in the hormone-refractory prostate cancer progression.
|
18757426 |
2008 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We finally report a significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline (P=0.007) in CRPC patients treated with abiraterone acetate.
|
19339269 |
2009 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.
|
19826044 |
2009 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
|
19890632 |
2010 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher levels of miR-21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml.
|
20842666 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These advantageous features of PSES-TSTA elicit superior gene expression capability for CRPC in comparison with the androgen-dependent PSA promoter-driven system.
|
21933883 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Abiraterone suppressed serum PSA levels and improved survival in two distinct CRPC xenografts: median survival of LuCaP35CR improved from 17 to 39 days (HR = 3.6, P = 0.0014) and LuCaP23CR from 14 to 24 days (HR = 2.5, P = 0.0048).
|
21807635 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of the AR regulated proteins PSA and PSMA were marginally affected by the decrease in C-terminal staining in CRPC samples.
|
22114732 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have demonstrated that an angiotensin II receptor blocker (ARB) has the potential to decrease serum prostate-specific antigen (PSA) level and improve performance status in CRPC patients.
|
22430461 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemonaïve patients with CRPC on CAB and PSA-doubling time (DT) < 3 months were eligible.
|
19959380 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotargeting the AR (with MDV3100) and CLU (with OGX-011) synergistically enhanced apoptotic rates over that seen with MDV3100 or OGX-011 monotherapy and delayed CRPC LNCaP tumor and prostate-specific antigen (PSA) progression in vivo.
|
23786771 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the majority of castration-resistant prostate cancer (CRPC), prostate-specific antigen (PSA), product of a gene that is almost exclusively regulated by the androgen receptor (AR), still acts as a serum marker reflecting disease burden, indicating that AR signaling is activated even under castrate level of serum androgen.
|
23896594 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
These effects were overcome by the combination of AZD5363 with the antiandrogen bicalutamide, resulting in synergistic inhibition of cell proliferation and induction of apoptosis in vitro, and prolongation of tumor growth inhibition and PSA stabilization in CRPC in vivo.
|
23966621 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given the fact that response to taxane therapy is measured by PSA decrease we have to consider that this might not reflect the true activity of AR in CRPC patients.
|
24260253 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
|
24026658 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase I clinical trial of the Ad/PSA vaccine in men with metastatic castrate-resistant prostate cancer demonstrated the safety of the vaccine even at the highest single dose permitted by the FDA.
|
24847764 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA half-time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause-specific mortality rates were determined during the 3-10 years follow-up.
|
25731771 |
2015 |